DermBiont’s SM-020 Produces “Prompt, Visible, and Robust” Tumor Responses in BCC
DermBiont’s SM-020 is performing well in an ongoing open label, multi-center Phase 2a study for the treatment of basal cell carcinoma (BCC), the Company reports. SM-020 is a first-in-class, patient-applied, topical kinase inhibitor. All nine treated BCCs (1 superficial, 4 nodular, and 4 infiltrating) across seven enrolled subjects to date showed “prompt, visible, and robust” […]